Travere Operating Cycle from 2010 to 2026
| TVTX Stock | USD 31.09 0.90 2.81% |
Operating Cycle | First Reported 2010-12-31 | Previous Quarter 384.87 | Current Value 547.38 | Quarterly Volatility 120.36838277 |
Check Travere Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Travere Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 15 M, Selling General Administrative of 318.9 M or Other Operating Expenses of 672.6 M, as well as many indicators such as Price To Sales Ratio of 5.83, Dividend Yield of 0.0 or PTB Ratio of 21.98. Travere financial statements analysis is a perfect complement when working with Travere Therapeutics Valuation or Volatility modules.
Travere | Operating Cycle | Build AI portfolio with Travere Stock |
The evolution of Operating Cycle for Travere Therapeutics provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Travere Therapeutics compares to historical norms and industry peers.
Latest Travere Therapeutics' Operating Cycle Growth Pattern
Below is the plot of the Operating Cycle of Travere Therapeutics over the last few years. It is Travere Therapeutics' Operating Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Travere Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Operating Cycle | 10 Years Trend |
|
Operating Cycle |
| Timeline |
Travere Operating Cycle Regression Statistics
| Arithmetic Mean | 521.47 | |
| Geometric Mean | 507.85 | |
| Coefficient Of Variation | 23.08 | |
| Mean Deviation | 104.21 | |
| Median | 547.38 | |
| Standard Deviation | 120.37 | |
| Sample Variance | 14,489 | |
| Range | 409 | |
| R-Value | (0.56) | |
| Mean Square Error | 10,574 | |
| R-Squared | 0.32 | |
| Significance | 0.02 | |
| Slope | (13.39) | |
| Total Sum of Squares | 231,817 |
Travere Operating Cycle History
About Travere Therapeutics Financial Statements
Travere Therapeutics investors use historical fundamental indicators, such as Travere Therapeutics' Operating Cycle, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Travere Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Operating Cycle | 384.87 | 547.38 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Travere Stock Analysis
When running Travere Therapeutics' price analysis, check to measure Travere Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Travere Therapeutics is operating at the current time. Most of Travere Therapeutics' value examination focuses on studying past and present price action to predict the probability of Travere Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Travere Therapeutics' price. Additionally, you may evaluate how the addition of Travere Therapeutics to your portfolios can decrease your overall portfolio volatility.